BCL2 and ischemia reperfusion injury: TIIA has been demonstrated to decrease Bax/Bcl-2 ratio in a rat model of ischemia reperfusion injuries in vivo[25], and to regulate Bax/Bcl-2 ratio in neonatal cardiomyocytes treated with doxorubicin [15].